ArticleBone marrow transplantation2024

In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT.

Meral Beksac et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.